**QUEEN'S
UNIVERSITY
BELFAST**

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

VX17-445-103 Trial Group (2019). Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. *Lancet*, 394(10212), 1940. [https://doi.org/10.1016/S0140-6736\(19\)32597-8](https://doi.org/10.1016/S0140-6736(19)32597-8)

Published in:
Lancet

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright © 2019 Elsevier Inc. except certain content provided by third parties.
This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>, which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for the *F508del* mutation: a double-blind, randomised, phase 3 trial

Harry G M Heijerman, MD,^{1,*} Edward F McKone, MD,^{2,*} Damian G Downey, MD,³ Eva Van Braeckel, MD,⁴ Steven M Rowe, MD,⁵ Elizabeth Tullis, MD,⁶ Marcus A Mall, MD,⁷ John J Welter, MD,⁸ Bonnie W Ramsey, MD,⁹ Charlotte M McKee, MD,¹⁰ Gautham Marigowda, MD,¹⁰ Samuel M Moskowitz, MD,¹⁰ David Waltz, MD,¹⁰ Patrick R Sosnay, MD,¹⁰ Christopher Simard, MD,¹⁰ Neil Ahluwalia, MD,¹⁰ Fengjuan Xuan, PhD,¹⁰ Yaohua Zhang, PhD,¹⁰ Jennifer L Taylor-Cousar, MD,^{11,*} Karen S McCoy, MD^{12,*} on behalf of the VX17-445-103 Trial Group

*Equal contributions

¹Department of Pulmonology, University Medical Center Utrecht, Utrecht, the Netherlands; ²St Vincent's University Hospital and University College Dublin School of Medicine, Dublin, Ireland; ³Centre for Experimental Medicine, Queen's University Belfast, Northern Ireland, United Kingdom; ⁴Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; ⁵Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; ⁶Division of Respiriology, St Michael's Hospital, University of Toronto, Toronto, , Canada; ⁷Department of Pulmonology, Immunology and Intensive Care Medicine, Charité–Universitätsmedizin Berlin, Berlin Germany; Berlin Institute of Health, Berlin, Germany; and German Center for Lung Research, Berlin, Germany; ⁸Division of Pediatric Pulmonology, Allergy, Immunology, and Sleep Medicine, New York Medical College, Valhalla, NY, USA; ⁹Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, US; ¹⁰Vertex Pharmaceuticals Incorporated, Boston MA, US; ¹¹Department of Medicine and Pediatrics, National Jewish Health, Denver, CO, USA;

27 ¹²Department of Pediatrics, Nationwide Children's Hospital, Ohio State University, Columbus,
28 OH, USA

29

30 Corresponding author

31 Prof Harry Heijerman, MD, PhD

32 Department of Pulmonology, University Medical Center Utrecht

33 Heidelberglaan 100 3584CX, Utrecht

34 The Netherlands

35 h.g.m.heijerman@umcutrecht.nl

36 Phone: +31 88 75 561 80

37 Mobile: +31 6 2123 51 61

38

39 **Word count: 3031** (limit: 3500 words)

40 **Tables/figures:** 3 tables, 4 figures (no limit specified)

41 **References:** 28 (limit: 30)

42 **Abstract word count:** 309 (limit: 300)

43

Summary

Background

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved using the combination of a CFTR corrector and potentiator in people with CF (pwCF) homozygous for *F508del*. The addition of elexacaftor (ELX; VX-445), a next-generation CFTR corrector, to tezacaftor/ivacaftor (TEZ/IVA) further improved *F508del*-CFTR function and clinical outcomes in a phase 2 study in pwCF homozygous for *F508del*.

Methods

A phase 3, multi-centre, randomised, double-blind, active-controlled trial of ELX in triple combination with TEZ/IVA (ELX/TEZ/IVA) in pwCF homozygous for *F508del* was conducted. Eligible participants were aged ≥ 12 years with stable disease and percent predicted forced expiratory volume in 1 second (ppFEV₁) of 40 to 90, inclusive. After a four-week TEZ/IVA run-in, participants were randomised 1:1 to four weeks of ELX/TEZ/IVA versus TEZ/IVA alone. The primary endpoint was absolute change from baseline (measured at the end of the TEZ/IVA run-in) in ppFEV₁ at week 4. Key secondary endpoints were absolute change in sweat chloride and CF Questionnaire–Revised respiratory domain (CFQ-R RD) score. ClinicalTrials.gov, number **NCT03525548**.

Findings

Between August and December 2018, 113 participants were enrolled. Following the run-in, 107 participants were randomised and completed the 4-week treatment period. The ELX/TEZ/IVA group had improvements in ppFEV₁ (10.0 percentage points, 95% CI 7.4 to 12.6, $p < 0.0001$), sweat chloride concentration (-45.1 mmol/L, 95% CI -50.1 to -40.1, $p < 0.0001$), and CFQ-R RD score (17.4 points, 95% CI 11.8 to 23.0, $p < 0.0001$) compared with the TEZ/IVA

group. ELX/TEZ/IVA was well tolerated, with no discontinuations. Most adverse events were mild or moderate; serious adverse events occurred in 4% (n=2) of participants receiving ELX/TEZ/IVA and 2% (n=1) receiving TEZ/IVA.

Interpretation

ELX/TEZ/IVA provided clinically robust benefit vs TEZ/IVA alone with a favourable safety profile and demonstrates the potential to lead to transformative improvements in the lives of pwCF homozygous for *F508del*.

Funding

Vertex Pharmaceuticals Incorporated

Research in context

Evidence before this study

F508del, the most common defective form of the cystic fibrosis transmembrane conductance regulator protein (F508del-CFTR), can be corrected with currently available dual modulator combinations. Treatment of people with cystic fibrosis (pwCF) homozygous for *F508del* with these dual combinations has resulted in clinical improvements, but these improvements are lower in magnitude than those in the small subset of pwCF with genotypes highly responsive to available modulators. Addition of a next-generation CFTR corrector, elexacaftor (ELX; VX-445) to the existing CFTR modulator dual combination of tezacaftor/ivacaftor (TEZ/IVA) provided further benefit to this group of pwCF in a phase 2 study. The phase 2, double-blind, active-comparator study of ELX/TEZ/IVA in a small number of pwCF homozygous for *F508del* who were already receiving TEZ/IVA demonstrated that the triple drug combination was well tolerated and that the addition of ELX resulted in improvements in lung function, CFTR function, and a patient-reported outcome measure. A PubMed search of clinical trials, with no restrictions on publication date or language, using the terms “elexacaftor” and/or “VX-445” performed on 30 July 2019 revealed only one publication, describing the phase 2 study of ELX/TEZ/IVA.

Added value of this study

The trial reported here is the first phase 3 study of ELX/TEZ/IVA in pwCF homozygous for *F508del*. The results demonstrate, in a larger cohort, profound improvements in lung function, CFTR function, and respiratory-related quality of life compared with TEZ/IVA, along with a favourable safety profile. Evidence of systemic effect was also seen, with rapid improvements in body weight, an important predictor of survival in CF.

108 **Implications of all the available evidence**

109 The introduction of ELX/TEZ/IVA may extend highly effective CFTR modulator therapy to those
110 homozygous for *F508del*, a large proportion of pwCF. This advance in therapy is likely to modify
111 the natural course of the disease, leading to meaningful improvements in the lives of these
112 pwCF, profoundly impacting the face of CF care.

Introduction

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (*CFTR*) gene, which encodes for the CFTR protein, an anion transporter responsible for conductance of chloride and bicarbonate across epithelial surfaces in the airway, gastrointestinal and reproductive tracts, pancreas, and sweat glands.¹ Absence or reduction in the quantity and/or dysfunction of CFTR results in abnormal mucus secretions and multi-organ dysfunction, including pancreatic insufficiency and airway infection and obstruction.^{1,2} Chronic airway infection leads to progressive lung damage and eventually respiratory failure and premature death, with a median age at death of approximately 31 years.³⁻

⁵

Although it is known that there are more than 2000 variants of the *CFTR* gene,⁶ the most prevalent disease-causing *CFTR* mutation worldwide is *F508del*.^{4,5} Up to 90% of all people with CF (pwCF) have at least one copy of this mutation, and almost 50% of pwCF are homozygous for *F508del*.³⁻⁵

At present, the majority of treatments for pwCF address the downstream complications of CFTR dysfunction, independent of the *CFTR* genetic defect. In recent years, small molecules have been developed to address the basic defect through modulation of CFTR protein function. The first CFTR modulator therapy developed and approved was ivacaftor (IVA), a highly effective CFTR modulator in pwCF with *G551D*. IVA successfully potentiates this CFTR protein by increasing open probability, and led to unprecedented improvements in sweat chloride (an in vivo marker of CFTR function), lung function, respiratory-related quality of life, weight, and pulmonary exacerbations, sustained over the 48-week placebo-controlled trial.⁷

IVA alone does not restore F508del-CFTR function⁸; CFTR dysfunction caused by *F508del* is multifactorial, with defective protein processing and trafficking to the cell surface, reduced channel gating, and high turnover once at the cell surface.^{2,9,10} However, these defects can be partially overcome with a combination of CFTR modulators. Correctors such as lumacaftor and tezacaftor (TEZ) aid in processing and trafficking of the protein to the cell surface, and the potentiator ivacaftor addresses the gating defect. Studies of lumacaftor/IVA and TEZ/IVA showed improvements in lung function (2·6–4·0 percentage points of the percentage of predicted forced expiratory volume in 1 second [ppFEV₁]) and decreases in the rate of pulmonary exacerbations (a 35%–39% reduction) in pwCF homozygous for *F508del*.^{11,12} Given the multiple defects in F508del-CFTR affecting processing and trafficking, the magnitude of clinical improvements was consistent with the degree of correction of F508del-CFTR by a single CFTR corrector.^{13,14} To further enhance the modulation of F508del-CFTR, it was hypothesised that the addition of a second corrector acting with a complementary mechanism of action would be necessary to more fully restore CFTR processing and trafficking to a corrector-potentiator combination.

Elexacaftor (ELX; VX-445) is a next-generation CFTR corrector that was shown, in vitro, to significantly increase the amount of mature CFTR protein and CFTR activity when added to the combination of TEZ/IVA.¹⁵ ELX/TEZ/IVA showed encouraging results in a phase 2 study of this triple combination in a small sample of pwCF homozygous for *F508del*.¹⁵ The current phase 3, 4-week, randomised, controlled trial was conducted to confirm the superior efficacy of ELX/TEZ/IVA compared to TEZ/IVA and to evaluate safety in pwCF homozygous for *F508del*, as part of a development program that included a concurrent phase 3, 24-week, randomised, placebo-controlled trial in pwCF heterozygous for *F508del*.¹⁶

Methods

Trial Design and Oversight

A phase 3, multi-centre, randomised, double-blind, active-controlled trial of ELX in triple combination with TEZ/IVA in pwCF aged ≥ 12 years homozygous for *F508del* (ClinicalTrials.gov number NCT03525548) was conducted at 44 sites in four countries (Belgium, the Netherlands, the United Kingdom, and the United States) from 03 August 2018 to 28 December 2018.

The primary objective of the trial was to evaluate the efficacy of ELX in triple combination with TEZ/IVA, in comparison with TEZ/IVA alone, in pwCF homozygous for the *F508del* mutation.

An independent review board or ethics committee for each site approved the trial protocol and informed-consent forms. All enrolled participants, or their legal guardians, provided written informed consent (and assent, when appropriate).

Procedures

Because treatment with lumacaftor/IVA or TEZ/IVA is standard of care for pwCF homozygous for *F508del*, and to ensure a reliable on-treatment baseline before the triple combination treatment period, participants completed a 4-week TEZ/IVA run-in period following a 4-week screening period as described in Taylor-Cousar et al.¹⁶ Participants then received 4 weeks of treatment with either ELX 200 mg once daily in triple combination with TEZ 100 mg once daily and IVA 150 mg every 12 hours, or the dual combination of TEZ 100 mg once daily and IVA 150 mg every 12 hours. All drugs were administered orally. Selection of the dose of ELX was based on data from the phase 2 dose-ranging trial.¹⁵ TEZ and IVA were used at the approved dosages in both arms (figure 1).

Randomisation and masking

Participants were randomised in a 1:1 ratio by an interactive web response system to either ELX/TEZ/IVA or TEZ/IVA (see Supplementary Appendix for additional details). Placebo tablets were used to maintain the blind. Randomisation was stratified by ppFEV₁ (<70 vs ≥70, as determined during the run-in period) and age (<18 vs ≥18 years at the screening visit). At trial completion, participants were given the option to enrol in a 96-week open-label extension trial (VX17-445-105; ClinicalTrials.gov number NCT03525574).

Participants

Males and females aged ≥12 years with a confirmed diagnosis of CF homozygous for *F508del*, ppFEV₁ between 40 and 90 inclusive,¹⁷ and stable CF as judged by the investigators were recruited. All participants agreed to continue their usual standard-of-care treatment regimens throughout the trial period. The full inclusion and exclusion criteria are provided in the appendix.

Outcomes

The primary endpoint was the absolute change from baseline in ppFEV₁ at week 4. Key secondary endpoints were the absolute change from baseline at week 4 in sweat chloride concentration and in the respiratory domain of the Cystic Fibrosis Questionnaire–Revised (CFQ-R RD) score. Other secondary endpoints included safety and tolerability, as assessed by adverse events; clinical laboratory values; electrocardiograms; vital signs; and pulse oximetry.

Statistical analysis

Efficacy analyses included all randomised participants who received at least one dose of ELX/TEZ/IVA or TEZ/IVA in the treatment period. The absolute change from baseline in ppFEV₁ at week 4 was analysed using a mixed-effects model for repeated measures with change from baseline in ppFEV₁ at day 15 and week 4 as the dependent variables. The model included

treatment group, visit, and treatment-by-visit interaction as fixed effects, with the continuous baseline ppFEV₁ and age at screening (<18 vs ≥18 years) as covariates; the model used an unstructured covariance for the within-subject errors. The trial was designed for superiority. Assuming a within-group standard deviation of 7 percentage points and accounting for a 5% dropout rate at week 4, based on a two-sided, two-sample *t*-test at a significance level of 0·05, a sample size of 50 participants per treatment group was expected to achieve >90% power to detect a difference of 5 percentage points for the mean absolute change in the ppFEV₁ from baseline at week 4 between the two treatment groups. Key secondary endpoints of absolute change in sweat chloride concentration and in CFQ-R RD score were analysed using a similar mixed-effects model for repeated measures. A hierarchical testing procedure was used to control the overall type I error at an alpha of 0·05 for the primary endpoint and the key secondary endpoints tested. The safety analyses included all participants who received at least one dose of ELX/TEZ/IVA or TEZ/IVA in the treatment period. Safety data were summarised using descriptive statistics. Safety was monitored by an independent data monitoring committee.

Role of the funding source

The trial was designed by Vertex Pharmaceuticals, in collaboration with the authors. Data were collected by local site investigators and analysed by Vertex Pharmaceuticals Incorporated, in collaboration with the authors. All authors had full access to the trial data after the data were unblinded following final database lock and provided critical review and input. The corresponding author had final responsibility for the decision to submit for publication.

Results

Participant population

A total of 113 participants were enrolled in the trial. Following the 4-week TEZ/IVA run-in period, 107 participants were randomised and received at least one dose of trial drug; 55 were in the ELX/TEZ/IVA group and 52 were in the TEZ/IVA group. All 107 participants completed the 4-week treatment period and entered the open label ELX/TEZ/IVA extension trial (figure S1). Demographics and baseline characteristics were similar between intervention groups (table 1).

Efficacy

Treatment with ELX/TEZ/IVA led to a rapid improvement in ppFEV₁ above the baseline established after 4 weeks of treatment with TEZ/IVA (figure 2; table 2). The least squares mean difference between ELX/TEZ/IVA and TEZ/IVA in absolute ppFEV₁ was 10.0 percentage points (95% CI 7.4 to 12.6, $p < 0.0001$) at week 4.

Consistent with the clinically and statistically significant improvements observed in ppFEV₁, ELX/TEZ/IVA resulted in an improvement in sweat chloride concentration, with a least squares mean treatment difference of -45.1 mmol/L at week 4 (95% CI -50.1 to -40.1, $p < 0.0001$) compared with the TEZ/IVA group (figure 3A; table 2); the resulting mean value is below the diagnostic threshold for CF (figure 3B).^{18,19} The treatment difference in the change in CFQ-R RD score compared with TEZ/IVA was 17.4 points (95% CI 11.8 to 23.0, $p < 0.0001$). In the ELX/TEZ/IVA group, there was a least squares mean increase in the CFQ-R RD score of 16.0 points (95% CI 12.1 to 19.9) (figure 4; table 2), which exceeds the known 4-point improvement corresponding to the minimal clinically important difference in pwCF with stable disease.²⁰

The improvements in ppFEV₁ and sweat chloride concentration were consistent across all subgroups evaluated (figures S2 and S3). The histogram of treatment response for ppFEV₁, sweat chloride concentration, and CFQ-R RD score are shown in figures S4, S5, and S6.

At Week 4, treatment with ELX/TEZ/IVA resulted in a least squares mean increase in BMI of 0.60 kg/m² (95% CI 0.41 to 0.79, nominal p<0.0001) and a least squares mean body weight increase of 1.6 kg (95% CI 1.0 to 2.1, nominal p<0.0001) compared with TEZ/IVA. Because these analyses were not pre-defined, they were not corrected for multiplicity and p values are considered nominal.

Safety

ELX/TEZ/IVA was generally safe and well tolerated in this 4-week trial. Adverse events occurred in 32 (58%) participants in the ELX/TEZ/IVA group and in 33 (63%) participants in the TEZ/IVA group (table 3). The vast majority of AEs resolved during the study. No participants in the ELX/TEZ/IVA group and one (2%) in the TEZ/IVA group had an adverse event reported as severe. All other adverse events were mild or moderate. There were no adverse events that led to discontinuation of trial regimen in either treatment group. Serious adverse events occurred in two (4%) participants in the ELX/TEZ/IVA group (rash in one participant and pulmonary exacerbation in another) and one (2%) participant in the TEZ/IVA group (pulmonary exacerbation). The most common adverse events, those that occurred in >10% of participants in either treatment group, were cough and pulmonary exacerbation. Cough occurred more frequently in the ELX/TEZ/IVA group (15% vs 8%), whereas pulmonary exacerbation occurred more often in the TEZ/IVA group (2% vs 12%). Adverse events occurring in at least four participants in either treatment group are shown in table 3.

Investigators reported elevated transaminase levels as adverse events in two (4%) participants in the ELX/TEZ/IVA group and in one (2%) participant in the TEZ/IVA group; each investigator assessed the event as mild in severity and not serious. Review of laboratory results showed an incidence of alanine transaminase or aspartate transaminase $>3\times$, $>5\times$, and $>8\times$ the upper limit of normal in four (7%), two (4%), and zero participants in the ELX/TEZ/IVA group, respectively, compared with zero participants at any of these thresholds in the TEZ/IVA group. No participants had elevations of ALT/AST $>3\times$ upper limit of normal concurrent with an elevation in total bilirubin $>2\times$ upper limit of normal. No transaminase elevations required study drug interruption or discontinuation in this study.

Rash was seen in two (4%) participants in the ELX/TEZ/IVA group and two (4%) participants in the TEZ/IVA group. All four participants with rash were female, and all events were mild in severity; none required interruption or discontinuation of trial drugs. Both rash events in participants receiving ELX/TEZ/IVA resolved during the trial. One participant in each treatment group who had rash was receiving a concomitant hormonal oral contraceptive; the participant receiving ELX/TEZ/IVA discontinued the hormonal oral contraceptive.

The safety profile was consistent among subgroups (age, baseline ppFEV₁, gender and geographic region). There were no clinically relevant differences between the two treatment groups in vital signs, oximetry, physical examinations, laboratory abnormalities, or electrocardiogram findings.

Discussion

In this phase 3 trial in pwCF homozygous for *F508del*, in which all participants had a 4 week pre-treatment period with TEZ/IVA, treatment with ELX/TEZ/IVA resulted in substantial improvements in lung function, sweat chloride concentration, respiratory-related quality of life,

and nutritional parameters compared with TEZ/IVA alone. Similar results were observed across all subgroups. ELX/TEZ/IVA was well tolerated, with a safety profile comparable to that in the control group using TEZ/IVA alone. The most commonly reported adverse events were consistent with typical manifestations of CF.

To date, clinical results following treatment with IVA in pwCF with the *G551D* mutation are considered to be the benchmark for treatment with CFTR modulators. Following 24 weeks of IVA therapy, the 10.6 percentage point increase in ppFEV₁ and a substantial reduction in pulmonary exacerbations compared with placebo⁷ were sustained in a 96-week trial.²¹ IVA therapy has also been shown to be associated with a decreased need for lung transplant and improved survival with long-term use.^{22,23} Comparatively, pwCF homozygous for *F508del* treated with TEZ/IVA experienced a 4-percentage point increase in ppFEV₁ compared with placebo.¹² The 10.0-percentage point improvement in lung function with ELX/TEZ/IVA compared with TEZ/IVA in pwCF homozygous for *F508del* observed in the current trial is similar to that seen with IVA in pwCF and the *G551D* mutation.⁷ Data from the 96-week open-label study of ELX/TEZ/IVA in pwCF who are homozygous or heterozygous for *F508del* (NCT03525574) will be obtained to confirm these outcomes over a longer period of time.

To understand how the effects of ELX/TEZ/IVA in pwCF homozygous for *F508del* would have compared if a placebo control, rather than an active control, had been used, the improvements in clinical outcomes and CFTR function previously reported for TEZ/IVA over placebo in this population should be considered. In the current trial, participants started ELX/TEZ/IVA after a run-in with TEZ/IVA. The treatment effect of TEZ/IVA is reflected in the baseline sweat chloride concentration of 90 mmol/L, which is comparable to that observed at the end of the TEZ/IVA versus placebo trial,¹² and approximately 10 mmol/L below that in untreated pwCF homozygous for *F508del*. The addition of ELX to TEZ/IVA in this trial resulted in a mean sweat chloride

concentration of 48·0 mmol/L at week 4, which is below the diagnostic threshold for CF (60 mmol/L).¹⁸ Likewise, the improvements in lung function (10 percentage points in ppFEV₁) observed with ELX/TEZ/IVA compared with TEZ/IVA in the present trial may be taken in context with the demonstrated impact of TEZ/IVA in this population (a 4-percentage point improvement in ppFEV₁ compared with placebo).¹² It is useful to frame these results observed in trial participants taking ELX/TEZ/IVA, and the magnitude of CFTR modulation they represent, in the context of the overall degree of CFTR modulation and the clinical benefits observed in pwCF and a *G551D* mutation treated with IVA.⁷

Benefits of ELX/TEZ/IVA were also observed on other important endpoints, including surrogates for nutritional health. Although the treatment duration in this trial was only 4 weeks, there was an increase in BMI and weight in the ELX/TEZ/IVA group compared with those who received TEZ/IVA alone. Improvements in weight and BMI were not observed in a 24-week study of TEZ/IVA in the same population.¹² Weight and BMI in pwCF are closely correlated with improvements in lung function and are independent predictors of survival.^{24,25} The improvements in weight and BMI over 4 weeks observed herein are promising.

Pulmonary exacerbations are important life events for pwCF and are associated with a greater rate of lung function decline and decreased survival.^{24,26} Although not defined as an efficacy outcome in this 4-week trial, there was a reduction in reported adverse events of infective pulmonary exacerbation of CF in the ELX/TEZ/IVA group relative to the TEZ/IVA group. These results and those observed in the longer companion trial in pwCF heterozygous for *F508del* in which treatment with ELX/TEZ/IVA resulted in a 63% reduction in pulmonary exacerbations compared with placebo²⁷ provide encouraging evidence of the effect of ELX/TEZ/IVA on pulmonary exacerbations compared with the current standard of care.

The majority of phase 3 trials assessing the efficacy of CFTR modulators have used treatment periods of 24 weeks or longer, and a potential limitation of this trial is the 4-week duration.^{7,11,12} However, a 4-week duration was selected for this trial based on (1) observations that short-term changes in lung function have consistently been demonstrated within 4 weeks of treatment with CFTR modulators in previous randomised controlled trials, and these short-term improvements in lung function have been sustained through 24 weeks of treatment,^{7,11,12} and (2) the premise that the safety profile observed in the concurrent 24-week trial of ELX/TEZ/IVA in pwCF heterozygous for *F508del*²⁷ would be applicable to pwCF homozygous for *F508del*. The latter assumption is supported by prior data with CFTR modulators showing comparable safety data across numerous CF genotypes.^{7,8,28} Long-term outcomes of ELX/TEZ/IVA in will be evaluated in ongoing investigations including the open-label extension of this trial and post approval observational studies.

In conclusion, this phase 3 trial demonstrated the efficacy and safety of ELX/TEZ/IVA in participants homozygous for *F508del* over the 4-week study period. In the concurrent phase 3 trial in pwCF in whom a single *F508del* was responsible for the treatment response, marked improvements in clinical outcomes substantiate the ability of ELX/TEZ/IVA to restore *F508del*-CFTR function.²⁷ Based on the known impact of the benchmark therapy IVA in a small subset of pwCF, the introduction of ELX/TEZ/IVA is likely to lead to meaningful improvements in the lives of pwCF homozygous for *F508del*. This degree of CFTR modulation in such a large proportion of pwCF may profoundly impact the face of CF care.

Author contributions

The VX17-445-103 study was designed by the study sponsor, Vertex Pharmaceuticals Incorporated, in collaboration with EFC, SMR, ET, MAM, BWR, and JLT-C. HGMH, DGD, EVB, JJW, JLT-C, and KSM enrolled participants, and collected the data, which were analysed by the

391 sponsor. All authors participated in the analysis and interpretation of study data, drafting and
392 critically revising the manuscript for important intellectual content, and gave final approval of the
393 manuscript for publication.

395 **Declaration of interest**

396 HGMH reports speaker fees from Chiesi, Horizon Pharma, PTC Therapeutics, TEVA, and
397 Vertex; fees for advisory board participation from Vertex and PTC Therapeutics. EFM reports
398 grants from Gilead and Vertex, for which his institution St Vincent's University Hospital received
399 payment; consulting fees from Vertex and Proteostasis; non-financial support from Novartis.
400 DGD reports grants from Proteostasis and Vertex, for which his institution Queen's University
401 Belfast received payment; speaker fees from Vertex; honoraria from Proteostasis. EVB reports
402 research grants from Vertex, Galapagos and Zambon, for which her institution Ghent University
403 Hospital received payment; fees for advisory board participation for Vertex. SMR reports
404 research grants from AstraZeneca, Bayer, Celtaxys, Eloxx, Forest Research Institute,
405 Galapagos/AbbVie, N30/Nivalis, Novartis, PTC Therapeutics, and Vertex, for which his
406 institution the University of Alabama at Birmingham received payment; consulting fees from
407 Bayer, Celtaxys, Novartis, Renovion, and Vertex; fees for advisory board participation for
408 Vertex. ET reports grants from AbbVie, Proteostasis, and Vertex, for which her institution St
409 Michael's Hospital received payment; personal fees from Proteostasis and Vertex. MAM reports
410 research grants from Vertex, for which his institution Charité-Universitätsmedizin Berlin
411 received payment; consulting fees from Bayer, Galapagos, and Sterna Biologicals; fees for
412 consulting and advisory board participation from Arrowhead, Boehringer Ingelheim, Enterprise
413 Therapeutics, Polyphor, ProQR Therapeutics, Sathera, Spyryx Bioscience, and Vertex; speaker
414 fees from Bayer, Boehringer Ingelheim, Celtaxys, and Vertex. JJW reports grants from Concert,
415 Proteostasis, and Vertex, for which his institution New York Medical College received payment.
416 CMM, GM, SMM, DW, PRS, CS, NA, FX, and YZ are employees of Vertex and may own stock

or stock options in that company. JLT-C reports research grants from Celtaxys, Bayer, Gilead, National Institutes of Health, Proteostasis, the Cystic Fibrosis Foundation, and Vertex, for which her institution National Jewish Health received payment; consulting fees from Celtaxys, Proteostasis, Santhera, and Vertex; fees for advisory board participation from Gilead, Protalix, and Vertex; speaker fees from Celtaxys, Proteostasis, and Vertex; and service on the Cystic Fibrosis Foundation Therapeutics Development Network Clinical Research Executive Committee and as Chair-Elect of the American Thoracic Society Clinical Problems Assembly Programming Committee. KSM reports research grants from Alcresta, Corbus, Novoteris, Proteostasis, Savara, Translate Bio, and Vertex, for which her institution Nationwide Children's Hospital received payment. BWR has nothing to disclose.

Data sharing

Vertex Pharmaceuticals Incorporated is committed to advancing medical science and improving patient health. This commitment includes the responsible sharing of clinical trial data with qualified researchers. Proposals for the use of these data will be reviewed by a scientific board. Approvals are at the discretion of Vertex Pharmaceuticals Incorporated and will be dependent on the nature of the request, the merit of the research proposed, and the intended use of the data. Please contact CTDS@vrtx.com if you would like to submit a proposal or need more information.

Acknowledgements

We thank the participants and their families for participating and the study investigators and coordinators for their contributions to the study. We thank the Cystic Fibrosis Foundation Therapeutics Development Network and the European Cystic Fibrosis Clinical Trials Network for their support of the study sites. The study was supported by Vertex Pharmaceuticals Incorporated. The National Institutes of Health provided grant support to the University of

Alabama at Birmingham (P30DK072482, R35HL135816, and U54TR001368) and Seattle
Children's Hospital (P30-DK-089507, 5UL1 TR 0002319, and 1U01TR 002487). Editorial
coordination and support were provided by Sarah Garber, PharmD and Swati Thorat, PhD. SG
and ST are employees of Vertex Pharmaceuticals Incorporated and may own stock or stock
options in the company. Editorial assistance was provided by Katherine Mills-Lujan, PhD, CMPP
of ArticulateScience LLC under the guidance of the authors and was supported by Vertex
Pharmaceuticals Incorporated.

References

1. Elborn JS. Cystic fibrosis. *Lancet* 2016; **388**: 2519–31.
2. Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. *Nature* 1991; **354**: 526–8.
3. Charman S, Connon R, Cosgriff R, Lee A, Carr S. UK Cystic Fibrosis Registry. Annual Data Report 2017. London, UK: Cystic Fibrosis Trust; 2018.
4. Zolin A, Orenti A, van Rens J, et al. ECFSPR Annual Report 2017. Karup, Denmark: European Cystic Fibrosis Society; 2019.
5. Marshall B, Faro A, Fink AK, et al. Cystic Fibrosis Patient Registry. 2017 Annual Data Report. Bethesda, MD; Cystic Fibrosis Foundation; 2018.
6. Cystic Fibrosis Mutation Database. CFMDB Statistics. April 25, 2011. <http://www.genet.sickkids.on.ca/StatisticsPage.html> (accessed August 23, 2019).
7. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 2011; **365**: 1663–72.
8. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. *Chest* 2012; **142**: 718–24.
9. Welsh MJ, Denning GM, Ostedgaard LS, Anderson MP. Dysfunction of CFTR bearing the delta F508 mutation. *J Cell Sci Suppl* 1993; **17**: 235–9.
10. Lukacs GL, Chang XB, Bear C, et al. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. *J Biol Chem* 1993; **268**: 21592–8.
11. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. *N Engl J Med* 2015; **373**: 220–31.
12. Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. *N Engl J Med* 2017; **377**: 2013–23.
13. Rabeh WM, Bossard F, Xu H, et al. Correction of both NBD1 energetics and domain interface is required to restore Δ F508 CFTR folding and function. *Cell* 2012; **148**: 150–63.
14. Mendoza JL, Schmidt A, Li Q, et al. Requirements for efficient correction of Δ F508 CFTR revealed by analyses of evolved sequences. *Cell* 2012; **148**: 164–74.
15. Keating D, Marigowda G, Burr L, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. *N Engl J Med* 2018; **379**: 1612–20.
16. Taylor-Cousar JL, Mall MA, Ramsey BW, et al. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. *ERJ Open Res* 2019; **5**: pii: 00082-2019.
17. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; **40**: 1324–43.
18. Farrell PM, White TB, Ren CL, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. *J Pediatr* 2017; **181S**: S4–S15.e1.
19. Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. *J Cyst Fibros* 2018; **17**: 153–78.
20. Quittner AL, Modi AC, Wainwright C, Otto K, Kiriara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic *Pseudomonas aeruginosa* airway infection. *Chest* 2009; **135**: 1610–8.
21. McKone EF, Borowitz D, Drevinek P, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). *Lancet Respir Med* 2014; **2**: 902–10.
22. Bessonova L, Volkova N, Higgins M, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. *Thorax* 2018; **73**: 731–40.

23. Volkova N, Moy K, Evans J, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. *J Cyst Fibros* 2019 Jun 10 [Epub ahead of print].
24. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. *Am J Epidemiol* 2001; **153**: 345–52.
25. Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. *J Pediatr* 2013; **162**(3): 530–5 e1.
26. Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. *Eur Respir J* 2012; **40**: 61–6.
27. Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-tezacaftor-ivacaftor for CF with a single *Phe509del* mutation. *N Engl J Med* 2019 (submitted).
28. Rowe SM, McColley SA, Rietschel E, et al. Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for *F508del-CFTR*. *Ann Am Thorac Soc* 2017; **14**: 213–9.

517 **Table 1. Demographics and Clinical Characteristics at Baseline.***

	Tezacaftor/Ivacaftor (n=52)	Elexacaftor/Tezacaftor/ Ivacaftor (n=55)
Female gender — no. (%)	28 (54)	31 (56)
Age at baseline		
Mean — yr	27·9 ±10·8	28·8 ±11·5
Distribution — no. (%) [†]		
≥12 to <18 yr	14 (27)	16 (29)
≥18 yr	38 (73)	39 (71)
Geographic region — no. (%)		
North America	33 (63)	34 (62)
Europe	19 (37)	21 (38)
Percentage of predicted FEV ₁		
Mean	60·2 ±14·4	61·6 ±15·4
Distribution — no. (%)		
<40% [‡]	4 (8)	6 (11)
≥40% to <70%	34 (65)	31 (56)
≥70% to ≤90%	14 (27)	18 (33)
>90%	0	0
Body-mass index, mean [§]	21·88 ±4·12	21·75 ±3·19

Sweat chloride concentration, mean — mmol/L	90·0 ±12·3	91·4 ±11·0
CFQ-R respiratory domain score, mean	72·6 ±17·9	70·6 ±16·2
<i>Pseudomonas aeruginosa</i> -positive within previous 2 years — no. (%)	31 (60)	39 (71)
Prior medication use, n (%) [¶]		
Dornase alfa		
Yes	48 (92)	51 (93)
No	4 (8)	4 (7)
Azithromycin		
Yes	25 (48)	33 (60)
No	27 (52)	22 (40)
Inhaled antibiotic		
Yes	28 (54)	35 (64)
No	24 (46)	20 (36)
Bronchodilator		
Yes	47 (90)	54 (98)
No	5 (10)	1 (2)
Inhaled hypertonic saline		
Yes	41 (79)	38 (69)

No	11 (21)	17 (31)
Inhaled corticosteroids		
Yes	28 (54)	36 (65)
No	24 (46)	19 (35)
CFTR modulator therapy		
Yes	34 (65)	32 (58)
No	18 (35)	23 (42)

CFQ-R=Cystic Fibrosis Questionnaire–Revised; FEV₁=forced expiratory volume in 1 second.

* Plus–minus values are means $\pm$ SD.

† Age distribution was calculated based on age at the time of screening.

‡ Although those eligible for enrolment were required to have a percent predicted FEV₁ $\geq$ 40 at screening, some participants experienced a decrease to a value $<$ 40 by baseline.

§ The body-mass index is the weight in kilograms divided by the square of the height in meters.

|| Scores on the CFQ-R range from 0 to 100, with higher scores indicating a higher participant-reported quality of life with regard to respiratory status.

¶ Includes medications administered during the 56 days before the first dose of trial drug in the treatment period.

530 **Table 2. Primary and Secondary Efficacy End Points.***

	Tezacaftor/ Ivacaftor (n=52)	Elexacaftor/ Tezacaftor/ Ivacaftor (n=55)	Difference (95% CI)	<i>P</i> Value†
Primary endpoint				
Absolute change in percentage of predicted FEV ₁ from baseline at week 4 (95% CI) — percentage points	0·4 (-1·4, 2·3)	10·4 (8·6, 12·2)	10·0 (7·4, 12·6)	<0·0001
Key secondary endpoints				
Absolute change in sweat chloride concentration from baseline at week 4 (95% CI) — mmol/L	1·7 (-1·9, 5·3)	-43·4 (-46·9, -40·0)	-45·1 (-50·1, -40·1)	<0·0001
Absolute change in CFQ-R respiratory domain score from baseline at week 4 (95% CI) — points	-1·4 (-5·4, 2·6)	16·0 (12·1, 19·9)	17·4 (11·8, 23·0)	<0·0001

CFQ-R=Cystic Fibrosis Questionnaire–Revised; FEV₁=forced expiratory volume in 1 second.

* Data are least squares means with 95% confidence intervals. The difference is the least squares mean difference between the elexacaftor/tezacaftor/ivacaftor group and the tezacaftor/ivacaftor group on the basis of the mixed-effects model for repeated measures. Baseline was defined as the end of the 4-week tezacaftor/ivacaftor run-in period.

† *P* values are for the between-group comparisons in all cases.

531
532
533
534
535
536
537
538

539 **Table 3. Adverse Events.**

	Tezacaftor/Ivacaftor (n=52)	Elexacaftor/Tezacaftor/ Ivacaftor (n=55)
	number of participants (percent)	
Any adverse event	33 (63)	32 (58)
Adverse event related to trial drug [†]	9 (17)	12 (22)
Adverse event, according to maximum severity		
Mild	21 (40)	23 (42)
Moderate	11 (21)	9 (16)
Severe	1 (2)	0
Life Threatening	0	0
Grade 3 or 4 adverse event	1 (2)	0
Serious adverse event	1 (2)	2 (4)
Serious adverse event related to trial drug [†]	0	1 (2)
Adverse event leading to discontinuation of trial drug	0	0
Adverse event leading to death	0	0

Most common adverse events [‡]		
Cough	4 (8)	8 (15)
Nasopharyngitis	2 (4)	4 (7)
Oropharyngeal pain	0	4 (7)
Upper respiratory tract infection	2 (4)	4 (7)
Headache	4 (8)	3 (5)
Haemoptysis	5 (10)	2 (4)
Pulmonary exacerbation [§]	6 (12)	1 (2)

Adverse events were coded using MedDRA version 21.1. When summarizing number and percent of participants, a participant with multiple events within a category was counted only once in that category.

[†] The determination of relatedness to trial drug was made by the investigators. When summarizing number of participants with (serious) adverse events related to the trial drug, adverse events with relationship of related, possibly related, and missing were counted.

[‡] The most common adverse events were those that occurred in at least four participants in either trial group.

[§] Per MedDRA 21.1, this adverse event is coded as infective pulmonary exacerbation of cystic fibrosis.

Figure 1. Study Design. Phase 3, randomised, double-blind, active-controlled, parallel-group, multicentre study. Eligible participants received tezacaftor/ivacaftor therapy during a 4-week run-in period. After completing the run-in period participants were randomised (1:1) to receive elexacaftor/tezacaftor/ivacaftor triple combination therapy or tezacaftor/ivacaftor for 4 weeks. Randomisation was stratified by percent predicted FEV₁ (<70 vs ≥70) determined during the run-in period and age (<18 vs ≥18 years) determined at the screening visit. ELX=elexacaftor; FEV₁=forced expiratory volume in 1 second; IVA=ivacaftor; QAM=once daily in the morning; QPM=once daily in the evening; TEZ=tezacaftor.

* Baseline was defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of trial drug in the treatment period (ie, ELX/TEZ/IVA vs TEZ/IVA).

† Participants who completed the trial regimen were eligible to enrol in a separate 96-week open-label extension study within 28 days after the last dose of trial drug; a safety follow-up visit was required for all participants unless they completed the week 4 visit and enrolled in the open-label extension study.

Figure 2. Absolute Change Over Time in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV₁) From Baseline. Data are least squares means based on a mixed-effects model for repeated measures, and error bars indicate standard errors; the dashed line indicates no change from baseline (measured at the end of the tezacaftor/ivacaftor run-in).

Figure 3. Absolute Change Over Time in Sweat Chloride Concentration From Baseline.

Panel A shows the absolute change in sweat chloride from baseline (measured at the end of the tezacaftor/ivacaftor run-in period). Panel B shows the mean sweat chloride concentration for each treatment group by visit. Data are least squares means based on a mixed-effects model for repeated measures for panel A and sample means for panel B; error bars indicate standard errors; the dashed line in panel A indicates no change from baseline; the dotted line in panel B indicates the 60 mmol/L diagnostic threshold for sweat chloride concentration.¹⁸

A

B

Figure 4. Absolute Change Over Time in Cystic Fibrosis Questionnaire–Revised

Respiratory Domain Score From Baseline. Scores range from 0 to 100, with higher scores indicating a higher participant-reported quality of life with regard to respiratory status. Data are least squares mean based on a mixed-effects model for repeated measures, and error bars indicate standard errors; the dashed line indicates no change from baseline; solid light grey line indicates a change in 4 points, which is the minimal clinically important difference for pwCF with stable disease.²⁰ CFQ-R=Cystic Fibrosis Questionnaire–Revised.